In this study, we demonstrated that downregulation of HNRNPH1 inhibits the potential tumorigenic both in vitro and in vivo, and can increase imatinib sensitivity, providing a rational drug design to prevent the expression of HNRNPH1 in BCR-ABL positive leukemia. This evidence concerns the gene ABL1 and leukemia.